Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Arginine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    Study title: VIALLATE J. Appréciation clinique du rôle de l'Arginine sur la nutrition et la croissance (Clinical estimate of the part played by arginine on nutrition and growth). Rev. Pédiatrie, VIII, 7, 419-423, 1972
    Active substance: ARGININE DIHYDRATE
    Study summary document link (including results): Arginine Option1.xls
    View full study record
    Document reference: 47170
    Study title: An uncontrolled study of the safety and efficacy of ceftazidime/arginine in children with serious or moderately serious bacterial infections.
    Active substance: CEFTAZIDIME
    Study summary document link (including results): Study CART03 Ceftazidime.xls
    View full study record
    Document reference: 47113
    Study title: Figueras−Nadal−C et al. Effectiveness and tolerability of ibuprofen−arginine versus paracetamol in children with fever of likely infectious origin. {ACTA−PAEDIATR− INT−J−PAEDIATR}, 2002, Vol/Iss/Pg. 91/4 (383−390)
    Active substance: CHLORPHENIRAMINE + DEXTROMETHORPHAN + PARACETAMOL
    Study summary document link (including results):
    View full study record
    Document reference: 23985
    Study title: A randomized, parallel, single dose, double-blind, double-dummy multicentre study to assess the antipyretic activity and tolerability of ibuprofen-arginine drops, in comparison to paracetamol in the treatment of likely infectious pediatric fever.
    Active substance: CLOPERASTINE
    Study summary document link (including results):
    View full study record
    Document reference: 24410
    Study title: AN 1993195892 19930101. TI Controlled trial with clonidine, arginine asparate, ornithine, alpha- ketoglutarate and cyproheptadine as growth stimulants in healthy children of short stature. AU Herranz-Jordan-B, Moreno-Romero-F, Cardesa-Garcia-J-J, Santos- Hurtado-I, Aparicio-Palomino-A, Requena-Guerrero-F. IN C/Ecija, 101,28230 Las Rozas, Spain. SO Anales Espanoles de Pediatria {AN-ESP-PEDIATR}, 1993, Vol/Iss/Pg. 38 /6 (509-515), ISSN: 0302-4342. YR 1993.AN 1993195892 19930101. TI Controlled trial with clonidine, arginine asparate, ornithine, alpha- ketoglutarate and cyproheptadine as growth stimulants in healthy children of short stature. AU Herranz-Jordan-B, Moreno-Romero-F, Cardesa-Garcia-J-J, Santos- Hurtado-I, Aparicio-Palomino-A, Requena-Guerrero-F. I...
    Active substance: CYPROHEPTADINE
    Study summary document link (including results):
    View full study record
    Document reference: 25259
    Study title: Ghigo E et al. Arginine but not pyridostigmine, a cholinesterase inhibitor, enhances the GHRH-induced GH rise in patients with anorexia nervosa. Biol Psychiatry. 1994 Nov 15;36(10):689-95Ghigo E et al. Arginine but not pyridostigmine, a cholinesterase inhibitor, enhances the GHRH-induced GH rise in patients with anorexia nervosa. Biol Psychiatry. 1994 Nov 15;36(10):689-95
    Active substance: PYRIDOSTIGMINE
    Study summary document link (including results):
    View full study record
    Document reference: 35201
    Study title: Ghigo E et al. Arginine potentiates the GHRH- but not the pyridostigmine-induced GH secretion in normal short children. Further evidence for a somatostatin suppressing effect of arginine. Clin Endocrinol (Oxf). 1990 Jun;32(6):763-7Ghigo E et al. Arginine potentiates the GHRH- but not the pyridostigmine-induced GH secretion in normal short children. Further evidence for a somatostatin suppressing effect of arginine. Clin Endocrinol (Oxf). 1990 Jun;32(6):763-7
    Active substance: PYRIDOSTIGMINE
    Study summary document link (including results):
    View full study record
    Document reference: 35213
    Study title: Guzzaloni G, Grugni G, Morabito F. Growth hormone response to hexarelin, growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen in prepubertal and early pubertal short children. Minerva Endocrinol. 1998 Dec;23(4):99-104Guzzaloni G, Grugni G, Morabito F. Growth hormone response to hexarelin, growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen in prepubertal and early pubertal short children. Minerva Endocrinol. 1998 Dec;23(4):99-104
    Active substance: PYRIDOSTIGMINE
    Study summary document link (including results):
    View full study record
    Document reference: 35192
    Study title: Procopio M et al. Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome. Int J Obes Relat Metab Disord. 1995 Feb;19(2):108-12Procopio M et al. Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome. Int J Obes Relat Metab Disord. 1995 Feb;19(2):108-12
    Active substance: PYRIDOSTIGMINE
    Study summary document link (including results):
    View full study record
    Document reference: 35199
    Study title: Figueras−Nadal−C et al. Effectiveness and tolerability of ibuprofen−arginine versus paracetamol in children with fever of likely infectious origin. {ACTA−PAEDIATR− INT−J−PAEDIATR}, 2002, Vol/Iss/Pg. 91/4 (383−390)Figueras−Nadal−C et al. Effectiveness and tolerability of ibuprofen−arginine versus paracetamol in children with fever of likely infectious origin. {ACTA−PAEDIATR− INT−J−PAEDIATR}, 2002, Vol/Iss/Pg. 91/4 (383−390)
    Active substance: PARACETAMOL AND DIPHENHYDRAMINE
    Study summary document link (including results):
    View full study record
    Document reference: 33383
    Study title: Figueras−Nadal−C et al. Effectiveness and tolerability of ibuprofen−arginine versus paracetamol in children with fever of likely infectious origin. {ACTA−PAEDIATR− INT−J−PAEDIATR}, 2002, Vol/Iss/Pg. 91/4 (383−390)
    Active substance: CODEINE_AND_PARACETAMOL
    Study summary document link (including results):
    View full study record
    Document reference: 24514
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 19:29:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA